Epacria Capital Partners, LLC Maxcyte, Inc. Transaction History
Epacria Capital Partners, LLC
- $123 Billion
- Q3 2025
A detailed history of Epacria Capital Partners, LLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Epacria Capital Partners, LLC holds 62,133 shares of MXCT stock, worth $98,170. This represents 0.08% of its overall portfolio holdings.
Number of Shares
62,133
Previous 62,133
-0.0%
Holding current value
$98,170
Previous $135 Million
27.52%
% of portfolio
0.08%
Previous 0.11%
Shares
2 transactions
Others Institutions Holding MXCT
# of Institutions
118Shares Held
71.8MCall Options Held
0Put Options Held
0-
Cadian Capital Management, LP New York, NY8.23MShares$13 Million0.78% of portfolio
-
Mirabella Financial Services LLP London, X08.2MShares$13 Million1.16% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$12.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY6.7MShares$10.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.59MShares$8.83 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $161M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...